NewAmsterdam Pharma N.V. Statistics
Share Statistics
NewAmsterdam Pharma N.V. has 106.83M shares outstanding. The number of shares has increased by 19.68% in one year.
| Shares Outstanding | 106.83M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 18.68% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 54.48M |
| Failed to Deliver (FTD) Shares | 390.82K |
| FTD / Avg. Volume | 48.66% |
Short Selling Information
The latest short interest is 2.58M, so 2.42% of the outstanding shares have been sold short.
| Short Interest | 2.58M |
| Short % of Shares Out | 2.42% |
| Short % of Float | 5.12% |
| Short Ratio (days to cover) | 1.88 |
Valuation Ratios
The PE ratio is -5.19 and the forward PE ratio is -13.1.
| PE Ratio | -5.19 |
| Forward PE | -13.1 |
| PS Ratio | 71.91 |
| Forward PS | 123.6 |
| PB Ratio | 3.18 |
| P/FCF Ratio | -6.5 |
| PEG Ratio | n/a |
Enterprise Valuation
NewAmsterdam Pharma N.V. has an Enterprise Value (EV) of 577.36M.
| EV / Earnings | -3.26 |
| EV / Sales | 45.24 |
| EV / EBITDA | -3.26 |
| EV / EBIT | -3.48 |
| EV / FCF | -4.09 |
Financial Position
The company has a current ratio of 6.95, with a Debt / Equity ratio of 0.
| Current Ratio | 6.95 |
| Quick Ratio | 6.95 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -24.38 |
Financial Efficiency
Return on equity (ROE) is -0.61% and return on capital (ROIC) is -57.46%.
| Return on Equity (ROE) | -0.61% |
| Return on Assets (ROA) | -0.51% |
| Return on Capital (ROIC) | -57.46% |
| Revenue Per Employee | 205.85K |
| Profits Per Employee | -2.85M |
| Employee Count | 62 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 27.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 35.13% in the last 52 weeks. The beta is 0, so NewAmsterdam Pharma N.V.'s price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 35.13% |
| 50-Day Moving Average | 23.11 |
| 200-Day Moving Average | 19.78 |
| Relative Strength Index (RSI) | 44.28 |
| Average Volume (20 Days) | 803.18K |
Income Statement
In the last 12 months, NewAmsterdam Pharma N.V. had revenue of 12.76M and earned -176.94M in profits. Earnings per share was -2.15.
| Revenue | 12.76M |
| Gross Profit | 12.76M |
| Operating Income | -165.73M |
| Net Income | -176.94M |
| EBITDA | -176.86M |
| EBIT | -165.73M |
| Earnings Per Share (EPS) | -2.15 |
Balance Sheet
The company has 340.45M in cash and 60.00K in debt, giving a net cash position of 340.39M.
| Cash & Cash Equivalents | 340.45M |
| Total Debt | 60.00K |
| Net Cash | 340.39M |
| Retained Earnings | -316.97M |
| Total Assets | 439.19M |
| Working Capital | 396.62M |
Cash Flow
In the last 12 months, operating cash flow was -141.22M and capital expenditures -24.00K, giving a free cash flow of -141.24M.
| Operating Cash Flow | -141.22M |
| Capital Expenditures | -24.00K |
| Free Cash Flow | -141.24M |
| FCF Per Share | -1.72 |
Margins
Gross margin is 100%, with operating and profit margins of -1.30K% and -1.39K%.
| Gross Margin | 100% |
| Operating Margin | -1.30K% |
| Pretax Margin | -1.26K% |
| Profit Margin | -1.39K% |
| EBITDA Margin | -1.39K% |
| EBIT Margin | -1.30K% |
| FCF Margin | -1.11K% |
Dividends & Yields
NAMS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9.05% |
| FCF Yield | -5.56% |
Analyst Forecast
The average price target for NAMS is $36.5, which is 53.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $36.5 |
| Price Target Difference | 53.6% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 25.94 |
| Piotroski F-Score | 3 |